Korean drug firms step up race to take on Wegovy, Mounjaro
Korean pharmaceutical companies are rushing to develop their own alternatives to blockbuster weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, accelerating efforts to enter the booming obesity treatment market with competitively priced medications, improved tolerability and innovative delivery methods.
Hanmi Pharmaceutical appears to be leading the race so far, as it has been carrying out Phase 3 clinical trials of Efpeglenatide, a glucagon-like peptide-1, or GLP-1, drug that can be injected once a week, in Korea since January this year. The drug developer plans to complete the third and final clinical studies in September, eyeing the launch of the weight-loss medication in the second half of next year.
According to Hanmi, the drug uses a slow absorption method to offer improved tolerability and fewer gastrointestinal side effects. It also has reportedly displayed impacts in reducing cardiovascular and kidney disease risks by over 35 percent.
A Hanmi official said the price of its weight-loss drug is expected to be lower than the imported ones such as Wegovy, as it will be produced at the company's local plant in Pyeongtaek, Gyeonggi Province.
Hanmi is also concentrating on developing next-generation anti-obesity drugs.
The company presented early-stage studies of new drug candidates HM15275 and HM17321 at the 85th Scientific Sessions of the American Diabetes Association held in Chicago in June. The findings for HM15275 show more rapid and effective weight loss in comparison to anti-obesity drugs currently available in the market, while patients on HM17321 have achieved fat loss and muscle gain at the same time.
'Hanmi's research capabilities and development expertise in obesity and metabolic diseases are not only the best in Korea, but are increasingly recognized on the global stage,' said Choi In-young, head of R&D at Hanmi.
'As the global pharmaceutical landscape continues to shift toward obesity therapeutics, we will continue to strengthen our position as a true front-runner in this field.'
HK Inno.N obtained approval for an Investigational New Drug plan to conduct Phase 3 clinical trials of Ecnoglutide, a GLP-1 receptor agonist, in Korea from the Ministry of Food and Drug Safety. HK Inno.N got the license for Ecnoglutide from China's Sciwind Biosciences last year, securing exclusive rights to develop and commercialize the drug candidate in Korea.
According to recently released findings of Ecnoglutide's Phase 3 clinical studies in China, the drug demonstrated that people lost between 9 and 13 percent of their body weight on average after 40 weeks of treatment. HK Inno.N plans to complete Korean Phase 3 clinical trials by May 2028 to gear up for domestic commercialization.
While the administration of anti-obesity drugs has been mostly focused on injections, some drugmakers are turning to develop drugs that are easier to take.
Yuhan has partnered with Inventage Lab, a Korean biotechnology firm specializing in long-acting injectables, to develop IVL3021, a GLP-1 type medication that only requires an injection once a month, unlike the market-leading Wegovy's weekly dosage. They are also developing IVL3027, a Semaglutide-based oral medication candidate to help people lose weight, by using Inventage Lab's microsphere technology to maintain the stable release of the drug.
Ildong Pharmaceutical's research and development company Yunobia is also developing an oral GLP-1 receptor agonist-based oral medication candidate code-named ID110521156. According to its recently released findings, Phase 1 clinical studies showed that obese participants achieved an average 6.9 percent weight loss over a four-week period, with a maximum weight cut of 11.9 percent.
Daewon Pharmaceutical joined hands with local microneedle technology firm Raphas to develop DW1022, a weight loss patch candidate. After obtaining health authorities' approval for a Korean Phase 1 clinical trial in March last year, the company recently completed first phase studies while showcasing excellent tolerability and safety. Daewon Pharmaceutical said the patch-type drug candidate using Semaglutide, the main component of Wegovy, showed biological equivalence with the control group that used Wegovy with no differences in safety.
According to Morgan Stanley, the global market for obesity medications posted approximately $15 billion in sales last year and could reach as high as $150 billion in 2035. Worldwide market intelligence estimates that about 11 percent of the global population, or 1.3 billion people, could be eligible for anti-obesity drugs, with adoption rates among those eligible currently only at about 3 percent in the US and 1 percent in other countries.
'The adoption of weight-loss drugs is likely to accelerate in a pattern similar to structural changes in the technology cycle, such as the introduction of smartphones,' Morgan Stanley noted in a report. 'Patients' use will increase as they become more familiar and comfortable with the new products and as manufacturers address hurdles in production, distribution and regulatory issues.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
7 hours ago
- Korea Herald
Naver acquires Spain's top C2C platform Wallapop
Korean internet giant Naver said Tuesday that it has acquired a controlling stake in Spain's largest consumer-to-consumer platform, Wallapop, in a move to strengthen its foothold in the European digital marketplace. Naver said it acquired an additional 70.5 percent stake in Wallapop for 377 million euros ($436 million), bringing its total ownership to 100 percent. The Korean tech firm initially invested 115 million euros in 2021 and followed up with another 75 million euros in 2023. Wallapop boasts over 19 million monthly active users and facilitates peer-to-peer transactions across a wide range of categories, from everyday goods and electronics to used vehicles. The company has steadily grown its presence in the Iberian Peninsula and is expanding into southern European markets, including Italy and Portugal. The two companies have explored collaboration through technological integration, and Naver said it decided to acquire full ownership to unlock deeper synergy and accelerate growth. 'Wallapop has emerged as a formidable player in Spain's C2C landscape,' said Naver CEO Choi Soo-yeon. 'With the latest acquisition, we plan to combine Naver's technology, spanning search, advertising, payments and artificial intelligence, with Wallapop's user-friendly service to elevate the platform's capabilities and value proposition.' Naver has been actively investing in Europe since 2016 through funds managed by Korelya Capital, a venture capital firm established by Fleur Pellerin, former French Minister for Digital Economy. The company said it intends to use Wallapop as a strategic hub to deploy its technological expertise and e-commerce infrastructure across the continent. It will mark a significant step in Naver's global C2C expansion, adding Europe to its growing portfolio of platforms in North America, Korea and Japan, including Poshmark, Kream and Soda. 'With Wallapop's extensive product listings and rich storytelling potential, we aim to deepen our understanding of European consumer behavior and enhance the diversity of data in our AI ecosystem — ultimately strengthening Naver's global competitiveness,' Choi added.
Korea Herald
8 hours ago
- Korea Herald
Hanwha Life brings back dual CEOs for AI, global push
Hanwha Life Insurance's new co-CEOs, Vice Chair Kwon Hyeuk-woong and President Lee Kyung-keun, officially took office on Tuesday, reinstating a dual leadership structure for the first time in six years. Their appointments were approved at a temporary shareholders' meeting and board session held the same day. The top executives will lead the Korean insurer with independent representation rights. In a letter to employees, Kwon and Lee set a vision to transform Hanwha Life into a 'life solutions partner,' offering services that go beyond traditional insurance and are tailored to each stage of a customer's life. To achieve this, the new CEOs emphasized the need to strengthen artificial intelligence capabilities, calling AI essential for navigating the tech-driven transformation of the financial sector. 'As AI accelerates the arrival of a hyper-personalized era, the insurance industry must also deliver individualized solutions based on a deep understanding of each customer's life,' they said. The two leaders also stressed their commitment to expanding Hanwha Life's global business. 'We will continue pursuing our vision of becoming a global, comprehensive financial group; advancing our business in East Asia, including Indonesia, where we have established a full-service financial system; and expanding our presence in the US, where we've entered the brokerage sector,' they said. This year, Hanwha Life made a strategic investment in Indonesia's Nobu Bank and acquired a controlling stake in US brokerage firm Velocity Clearing. Both deals mark milestones for both the company and the Korean insurance industry as a whole. On Tuesday, the co-CEOs visited all 30 floors of the company's headquarters in Seoul's Yeouido district, greeting and encouraging the firm's 1,800 employees. The leadership change follows the departure of former CEO Yeo Seung-joo, who is moving to Hanwha Group to head its management support division. The dual CEO structure returns after its suspension in 2019, when Yeo became the sole CEO. Kwon, formerly CEO of Hanwha Ocean, is expected to oversee overall operations, while Lee, previously CEO of Hanwha Life Financial Services — a wholly owned subsidiary responsible for the firm's sales force — will focus on insurance strategy and core business development.
Korea Herald
10 hours ago
- Korea Herald
Korea eyes 'K-Steel Act' to rescue industry from tariffs, China glut
Bipartisan bill aims to create presidential committee for master planning, offer financial support for next-gen steelmaking tech Korea is launching an aggressive policy push to rescue its steel industry from mounting global pressure, unveiling a bipartisan bill aimed at helping domestic producers hit hard by a 50 percent US tariff and a surge of low-cost Chinese products. Announced Monday by 106 lawmakers from both ruling and opposition parties, the proposed "K-Steel Act" outlines a long-term industrial strategy that frames steel as a vital base for national security and economic resilience. 'Korea's steel industry has grown rapidly since 1970. But today, it faces an unprecedented crisis, caught between the global push for carbon neutrality, a flood of cheap Chinese imports and steep tariffs from key trading partners,' lawmakers said in explaining the purpose of the bill. They warn that failure to act would leave Korea exposed on multiple fronts. A shrinking domestic steel base could ripple across its broader industrial ecosystem, threatening other sectors from shipbuilding to electric vehicle development. 'This bill is about both survival and transformation,' said Rep. Eoh Kiy-ku of the ruling Democratic Party of Korea and co-chair of the National Assembly Steel Forum. 'With bipartisan support, we plan to pass this quickly and follow up with additional legislation if needed.' Steel remains a pillar of Korea's manufacturing economy, accounting for 4.8 percent of national output and supporting more than 430,000 jobs. But that foundation is under threat. Despite a recent Korea-US tariff deal lowering duties on most goods to 15 percent, the US will maintain a 50 percent tariff on Korean steel. At the same time, the European Union's Carbon Border Adjustment Mechanism, set to launch next year, will impose extra costs on Korean steelmakers exporting to the EU unless they decarbonize fast. Korea's push comes as other major economies, including the US, EU and Japan, have already begun ramping up public support for their own steel sectors. From the US Inflation Reduction Act to EU climate subsidies, governments are blending industrial policy with climate action in a bid to secure supply chains while hitting net-zero targets. What's in the bill? The K-Steel Act lays out a comprehensive policy framework that would give the government a more direct role in shaping the industry's future. Central to the proposal is the creation of a presidential committee tasked with crafting five-year master plans and annual action roadmaps to steer the steel sector through economic and environmental challenges. To support the industry's green transition, the bill includes a wide range of financial incentives. These include subsidies, low-interest loans, tax breaks and production cost support for companies investing in hydrogen-based and other low-emission technologies. It also introduces 'green steel zones' -- designated areas where permitting and regulatory processes would be streamlined to encourage investment and innovation. The legislation also strengthens Korea's defensive trade measures. It calls for tighter rules of origin, curbs on low-quality steel imports and expanded authority for the government to counter unfair trade practices. In cases where market-driven restructuring proves insufficient, the government would be authorized to step in with financial and regulatory support, including temporary exemptions from antitrust laws for mergers deemed necessary to stabilize the industry.
